Recent Quotes (30 days)

You have no recent quotes
chg | %

Stellar Biotechnologies Inc  

(Public, CVE:KLH)   Watch this stock  
Find more results for KLH
-0.03 (-2.48%)
Delayed:   3:19PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.17 - 1.20
52 week 0.65 - 2.55
Open 1.20
Vol / Avg. 25,611.00/88,106.00
Mkt cap 93.81M
P/E     -
Div/yield     -
EPS -0.07
Shares 79.55M
Beta 3.24
Inst. own     -
Feb 9, 2015
Q1 2015 Stellar Biotechnologies Inc Earnings Release
Jan 13, 2015
Stellar Biotechnologies Inc at EBD Biotech Showcase
Dec 2, 2014
Stellar Biotechnologies Inc at LD Micro Conference

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -631.75% -2267.90%
Operating margin -623.26% -1536.70%
EBITD margin - -1494.16%
Return on average assets -38.63% -73.43%
Return on average equity -63.63% -306.63%
Employees 23 -
CDP Score - -


332 E Scott St
PORT HUENEME, CA 93041-2939
United States - Map
+1-805-4882800 (Phone)
+1-805-4882889 (Fax)

Website links


Stellar Biotechnologies, Inc. is a biotechnology company. Stellar is engaged in the research, development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH), and related products and technologies. KLH is a high molecular weight (HMW), immune-stimulating protein used in immunological applications, both as an active pharmaceutical ingredient (API) in certain immune therapies (such as for the treatment of cancer, infectious diseases and immune disorders) and as a finished product for testing immune status in patients and research settings. The Company products include HMW and subunit KLH protein in various grades, formulations and configurations, as well as certain preclinical in vitro diagnostic kits. Products offered include: Stellar KLH Protein for Vaccine Conjugation; Stellar KLH Protein for T-Cell Dependent Antibody Response (TDAR) and Immune Function Testing, and Custom KLH Formulations, Conjugations and Fill Finishes.

Officers and directors

Frank R. Oakes President, Chief Executive Officer, Director
Kathi Niffenegger CPA Chief Financial Officer, Secretary
Catherine Brisson Ph.D. Chief Operating Officer
Tessie Mary Che Ph.D. Director
Age: 60
Daniel E. Morse Ph.D. Director
Gregory T. Baxter Ph.D. Independent Director
David L. Hill Ph.D. Independent Director
Mayank D. Sampat Independent Director